The Medullary Thyroid Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Medullary Thyroid Cancer. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued products.

GlobalData tracks 48 drugs in development for Medullary Thyroid Cancer by 40 companies/universities/institutes. The top development phase for Medullary Thyroid Cancer is phase ii with 16 drugs in that stage. The Medullary Thyroid Cancer pipeline has 39 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Medullary Thyroid Cancer pipeline products market are: University of Pisa, Jiangsu Hengrui Medicine and Novartis.

The key targets in the Medullary Thyroid Cancer pipeline products market include Proto Oncogene Tyrosine Protein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogene c Ret or RET or EC 2.7.10.1), Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1), and Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1).

The key mechanisms of action in the Medullary Thyroid Cancer pipeline product include Proto Oncogene Tyrosine Protein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogene c Ret or RET or EC 2.7.10.1) Inhibitor with 21 drugs in Pre-Registration. The Medullary Thyroid Cancer pipeline products include nine routes of administration with the top ROA being Oral and ten key molecule types in the Medullary Thyroid Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.

Medullary Thyroid Cancer overview

Medullary thyroid cancer (MTC) is a rare and aggressive type of thyroid cancer that originates from the C cells, which produce calcitonin, a hormone that regulates calcium levels in the blood. MTC accounts for 5-10% of all thyroid cancers and can be sporadic or inherited. Sporadic MTC occurs randomly, while inherited MTC is associated with a genetic condition called multiple endocrine neoplasia type 2 (MEN2). Symptoms of MTC may include a lump in the neck, hoarseness, diarrhea, and flushing. The main treatment for MTC is surgery to remove the thyroid gland and sometimes the nearby lymph nodes. Other treatments, such as radiation or medication, may be used depending on the stage and spread of the cancer. Early detection and treatment of MTC can improve the prognosis and quality of life of patients.

For a complete picture of Medullary Thyroid Cancer’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.